Workshop on rehabilitation education program on using Sign Language to teach English to deaf students to be held (See 'Corp Brief') Animal Husbandry is cash-generating sector, contributing 31% to total agricultural GVA (See 'Corp Brief') IPR - Copyright infringement by rogue websites who were using modern technology to hide their identities while unlawfully benefiting from JioStar's copyrighted works, calls for dynamic injunction: HC (See 'Legal Desk') Ministry of Mines launches 'Aspirational DMF Programme' (See 'Corp Brief') MSTC becomes engine of E-Transparency: Minister (See 'Corp Brief') IPR - Registrar of Trade Marks need to consider factors mentioned u/s 11(6) of Trade Marks, while deciding whether mark is known or recognized in relevant section of public: HC (See 'Legal Desk') Dholpur gets First Science Centre in Aspirational Districts Push: MoS (See 'Corp Brief') Mandaviya kicks off ASMITA Weightlifting League (See 'Corp Brief') IPR - Any entity cannot seek to set aside interim injunction passed against it in trademark infringement suit, merely because its business or IPO launch is jeopardized due to such injunction: HC (See 'Legal Desk') CCI okays stake in Smart Shift Logistics jointly by Kedaara Sapphire and Kedaara Capital Fund (See 'Corp Brief') BCCL revives Legacy Coal Mine via MDO Model (See 'Corp Brief') IPR - Requirement of sufficiency u/s 64(1)(h) of Patents Act, is satisfied when disclosure made in claims is sufficient to enable whole width of claimed invention to be performed: HC (See 'Legal Desk') CCI approves acquisition of certain businesses of UBS AG by 360 ONE Entities (See 'Corp Brief') IPR - Merely because ban on certain other applications has been lifted, is no ground for TikTok to claim that similar treatment shall also be allowed to it: HC (See 'Legal Desk') Centre plans Rs 5,000-Cr Investment to develop N-E Waterways: Sonowal (See 'Corp Brief') IPR - Defendants' attempt to use suit trademarks with sole intention of riding piggyback on plaintiffs' immense reputation, calls for injunction: HC (See 'Legal Desk') Chouhan, Dhami hold meeting on agriculture and rural development (See 'Corp Brief') IPR - Use of word 'ordinary' lead average consumer to infer that other Chyawanprash are either inferior, or spurious, as compared to Chyawanprash of Patanjali, which was claimed to be prepared by following ayurvedic traditions: HC (See 'Legal Desk') Rs.14,147 Cr transmission scheme discussed to evacuate solar power from key zone (See 'Corp Brief') IPR - Registering any mark already known to belong to another, without intent to use it bona fide, constitutes 'dishonest intention' and trademark squatting: HC (See 'Legal Desk') Family pension: 1451 cases redressed in first week of Special Campaign 2.0 (See 'Corp Brief') IPR - For software or computer programme to qualify u/s 3(k) of Patents Act, it should be more than mere sequence of instructions: HC (See 'Legal Desk') Why Family Businesses in India Are Losing Their Own Bloodline (See CORP EINSICHT)

Govt approves 11 bulk drug companies under PLI scheme for pharmaceuticals

Published: Feb 26, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 26, 2021: THE government has approved 11 companies to manufacture nine Key Starting Materials (KSMs), drug intermediates and Active Pharmaceutical Ingredients (APIs) under the Production Linked Incentive (PLI) scheme for bulk drugs.

The Ministry of Chemicals and Fertilizers on Friday said that the businesses have committed investment of Rs 862.01 crore to set up their plants and will be generating employment for about 1,763 people.

Five companies have been approved to produce the fermentation-based bulk drugs -betamethasone, dexamethasone and prednisolone which are all steroids, and the antibiotics rifampicin and streptomycin.

Natural Biogenex (betamethasone, dexamethasone, prednisolone), SymbiotecPharmalab (prednisolone), Macleods Pharmaceutical (rifampicin), Optimus Drugs (vitamin B1, streptomycin), and Sudarshan Pharma (vitamin B1) were accorded approval.

Meanwhile, six companies were approved for producing three chemical synthesis-based bulk drugs with the intermediary 1,1 Cyclohexane Diacetic Acid being produced by Saraca Laboratories, Emmennar Pharma and Hindys Lab. Aarti Speciality Chemicals (2-Methyl-5NitroImidazole), Meghmani (Para amino phenol) and Sadhana Nitro Chem (para amino phenol) were also approved.

The commercial production is projected to commence from April 1, 2023, onwards and the disbursal of production linked incentive by the government over the six years period would be up to a maximum of Rs. 4,870 crore.

By encouraging local production through the PLI scheme, the government aims to reduce its import dependence on critical bulk drugs or raw material which can be as high as 80-100 per cent. The scheme focuses on setting up greenfield plants at a cost of Rs. 6,940 crore in four different target segments.

The government kicked off the PLI approval for bulk drugs in January. Since then, it has approved a total of 19 applications with committed investment of Rs. 4,623.01 crore.

TIOL CORP SEARCH

TIOL GROUP WEBSITES